• HIRE Technologies (HIRE) announces its financial results for the quarter and year ended December 31, 2021
  • Record revenue of $27.7 million for the year, with YoY growth of $16.3 million, a 143 per cent increase
  • Gross margin of $12.2 million in FY 2021, 3.5x higher than 2020
  • Positive adjusted EBITDA of $0.1 million for the year 
  • HIRE Technologies CEO Simon Dealy sat down with Folake Ekwubiri to discuss the results
  • Hire Technologies Inc is focused on the acquisition of information technology, staffing, and HR consulting firms
  • Hire Technologies Inc. (HIRE) opened trading at C$0.17 per share

HIRE Technologies (HIRE) has announced its financial results for the quarter and year ended December 31, 2021.

Highlights include:

  • Record revenue of $27.7 million for the year, with year-over-year growth of $16.3 million, a 143 per cent increase
  • $8.1 million in revenue for the quarter ended December 31, 2021, marking HIRE’s fifth consecutive quarter of sequential record revenues
  • Organic growth of 32 per cent for the year
  • Gross margin for the year of $12.2 million, 3.5x higher than 2020.
  • Gross margin for the quarter of $4.0 million, 204 per cent higher than the quarter ended December 31, 2020
  • Adjusted EBITDA of $0.1 million for the year and $0.3 million for the quarter

Simon Dealy, CEO of HIRE, sat down with Folake Ekwubiri to discuss the numbers.

Hire Technologies Inc is focused on the acquisition of information technology, staffing, and HR consulting firms.

Hire Technologies Inc. opened trading at C$0.17 per share.

More From The Market Online
An AI generated photo of a stethoscope on a computerized setting

How one company is disrupting PoC testing

When it comes to Gemina Laboratories Ltd. (CSE:GLAB), the Canada and U.K.-based company is progressing a range of PoC diagnostic technologies.
Bear and bull statues wearing Christmas hats

@ the Bell: TSX advances to start off Christmas trading week

Canada’s TSX index closed higher on Monday thanks to large-cap gains, despite weakness in real estate and telecom stocks.
Doctor with a bladder replica

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient’s Guide

As a patient with BCG-Unresponsive NMIBC CIS, bladder removal is far from the only option on the table in 2024.